BPI-460372 — Investigational Agent
KRAS Inhibitor · Phase 1 · Betta Pharmaceuticals
Mechanism of Action
Oral pan-KRAS inhibitor that targets multiple oncogenic KRAS mutant variants (beyond G12C), suppressing active RAS signaling across a broad mutational spectrum to overcome the limitations of allele-specific inhibitors and address acquired resistance.
Investigational Indications
- KRAS-mutant NSCLC
- KRAS-mutant pancreatic cancer
- KRAS-mutant colorectal cancer
- Other KRAS-mutant advanced solid tumors